Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© Springer International Publishing Switzerland 2017. It can be argued correctly that any vaccine that reduces the reproductive potential of a pathogen is a transmission-blocking vaccine; in the context of malaria, a cover-all term ‘vaccines that interrupt malaria transmission’ (VIMT) has recently been invoked to describe such products. Vaccines that impact the transmission of the malaria parasite from the vertebrate host to the mosquito vector-previously termed transmission-blocking vaccines (TBV)-have consequently been renamed ‘sexual, sporogonic and mosquito stage vaccines (SSM-VIMT)', to distinguish them from pre-erythrocytic vaccines targeting the sporozoite as it travels from the mosquito to the hepatocyte. In this chapter, we confine our discussion to TBV as classically described.

Original publication

DOI

10.1007/978-3-319-45210-4_12

Type

Chapter

Book title

Malaria: Immune Response to Infection and Vaccination

Publication Date

01/01/2017

Pages

241 - 272